3-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]-4H-1,2,4-triazole | 633317-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]-4H-1,2,4-triazole
• 英文别名: 3-(1-(4-chlorophenyl)cyclobutyl)-4-methyl-5-(4-(trifluoromethoxy)phenyl)-4H-1,2,4-triazole；3-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]-1,2,4-triazole
• CAS: 633317-00-7
• 化学式: C₂₀H₁₇ClF₃N₃O
• 分子量: 407.823
• InChiKey: ORACBUKRQCFDKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(4-chlorophenyl)cyclobutanecarbohydrazide 、 在 三乙胺 作用下， 以 甲苯 为溶剂， 生成 3-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]-4H-1,2,4-triazole
  参考文献：
  名称：

  4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I

  摘要：

  4-Methyl-5-phenyl-(1,2,4)-triazoles were identified as selective inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). They were active in vitro and in an in vivo mouse pharmacodynamic (PD) model. The synthesis and structure activity relationships are presented. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.013

文献信息

• 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1532122B1

  公开（公告）日：2011-12-14
• US6730690B2
  申请人：——

  公开号：US6730690B2

  公开（公告）日：2004-05-04
• US7179802B2
  申请人：——

  公开号：US7179802B2

  公开（公告）日：2007-02-20
• [EN] INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION<br/>[FR] INHIBITION DE LA 11 BÊTA-HYDROXYSTÉROÏDE DÉHYDROGÉNASE DE TYPE 1 POUR UNE NEUROPROTECTION OCULAIRE
  申请人：BAUSCH & LOMB

  公开号：WO2009073460A2

  公开（公告）日：2009-06-11

  A composition comprises a material capable of controlling a level of cortisol in an ocular environment for effecting ocular neuroprotection in subjects in risk of developing or worsening an ocular neurodegenerative condition. Such a composition is injected into or implanted in the subject's posterior segment to provide such neuroprotection.